Completed A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease NCT02678689 Conditions Batten Disease, CLN2 Disease, CLN2 Disorder, +14 more Locations Nationwide Children's Hospital — Columbus, Ohio, United States Universitaetsklinikum Hamburg-Eppendorf — Hamburg, Germany Children's Hospital Bambino Gesù,IRCCS — Rome, Piazza, Italy Great Ormond Street Childrens Hospital — London, United Kingdom View Trial Details
Completed An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease NCT02485899 Conditions Batten Disease, CLN2 Disease, CLN2 Disorder, +14 more Locations Nationwide Children's Hospital — Columbus, Ohio, United States Universitaetsklinikum Hamburg-Eppendorf — Hamburg, Germany Children's Hospital Bambino Gesù,IRCCS — Rome, Piazza, Italy Great Ormond Street Childrens Hospital — London, United Kingdom View Trial Details
Completed A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease NCT01907087 Conditions Batten Disease, CLN2 Disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +13 more Locations Nationwide Children's Hospital — Columbus, Ohio, United States University Hamburg-Eppendorf — Hamburg, Germany Bambino Gesù Children's Hospital — Rome, Italy Guy's & St. Thomas NHS Foundation Trust — London, United Kingdom View more locations Show fewer locations Loading locations... View Trial Details
